secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001213900-25-043363
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology Q2 net loss widens to $7.7M; cash only $112, needs funding beyond May 2025
--------------------------------------------------------------------------------

- Net loss of $7.7M ($0.11 per share) vs $4.8M loss a year ago; R&D and G&A expenses increased due to launch activities.
- Cash and equivalents at March 31, 2025 totaled just $112; company requires additional capital to sustain operations beyond May 2025.
- Retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value.
- Advancing commercial launch of LYMPHIR (cutaneous T-cell lymphoma) after FDA approval; discussions with partners ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025043363/0001213900-25-043363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025043363/ea0241972-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-043363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer